<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04216134</url>
  </required_header>
  <id_info>
    <org_study_id>19517</org_study_id>
    <secondary_id>NCI-2019-08625</secondary_id>
    <secondary_id>19517</secondary_id>
    <secondary_id>P30CA033572</secondary_id>
    <nct_id>NCT04216134</nct_id>
  </id_info>
  <brief_title>68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer</brief_title>
  <official_title>A Phase I Study of 68GA-PSMA-11 PET Imaging for Biochemically Recurrent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects of 68GA-PSMA-11 PET imaging in patients with
      prostate cancer that has come back (recurrent). Gallium (68Ga) is a radiotracer that binds to
      a molecule, PSMA, that is found in abundance on most prostate cancer cells. PSMA is short for
      'prostate specific membrane antigen'. Diagnostic procedures, such as 68GA-PSMA-11 PET
      imaging, may help measure a patient's response to earlier treatment, and may help plan the
      best treatment for prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To provide clinical access to and assess the safety of the investigational agent Gallium
      Ga 68-labeled prostate specific membrane antigen (PSMA)-11 (68Ga-PSMA-11) positron emission
      tomography (PET) at City of Hope National Medical Center for patients co-enrolled on
      Institutional Review Board (IRB) 18517 treatment trial.

      OUTLINE:

      Patients receive gallium Ga 68-labeled PSMA-11 intravenously (IV) over less than 1 minute,
      and then undergo PET over 60 minutes.

      After completion of study, patients are followed up at 1-3 days, and then at 3 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">December 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Will be assessed by Common Terminology Criteria for Adverse Events version 5.0.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Biochemically Recurrent Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (68GA-PSMA-11 PET)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gallium Ga 68-labeled PSMA-11 IV over less than 1 minute, and then undergo PET over 60 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gallium Ga 68-labeled PSMA-11</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (68GA-PSMA-11 PET)</arm_group_label>
    <other_name>(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68Ga)Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-DKFZ-PSMA-11</other_name>
    <other_name>68Ga-HBED-CC-PSMA</other_name>
    <other_name>68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-PSMA</other_name>
    <other_name>68Ga-PSMA-11</other_name>
    <other_name>68Ga-PSMA-HBED-CC</other_name>
    <other_name>[68Ga] Prostate-specific Membrane Antigen 11</other_name>
    <other_name>[68Ga]GaPSMA-11</other_name>
    <other_name>Ga PSMA</other_name>
    <other_name>Ga-68 labeled DKFZ-PSMA-11</other_name>
    <other_name>Ga-68 labeled PSMA-11</other_name>
    <other_name>Gallium Ga 68 PSMA-11</other_name>
    <other_name>Gallium-68 PSMA</other_name>
    <other_name>Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>GaPSMA</other_name>
    <other_name>PSMA-HBED-CC GA-68</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo 68GA-PSMA-11 PET</description>
    <arm_group_label>Diagnostic (68GA-PSMA-11 PET)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biochemical recurrent prostate cancer

          -  Karnofsky performance status of &gt;= 50

          -  The effects of 68Ga-PSMA-11 on the developing fetus are unknown. For this reason,
             subjects must agree to use adequate contraception (hormonal or barrier method of birth
             control or abstinence) prior to study entry and for six months following duration of
             study participation when having sex with a pregnant female or with a female partner of
             childbearing potential

          -  Co-enrollment on IRB 18517

          -  Documented informed consent of the patient. All subjects must have the ability to
             understand and the willingness to sign a written informed consent

        Exclusion Criteria:

          -  Patients should not have any uncontrolled illness including ongoing or active
             infection

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to 68Ga-PSMA-11

          -  Use of another concomitant investigational therapy (with the exception of the
             investigational treatment given in IRB 18517) for prostate cancer within 7 days of
             scheduled 68Ga-PSMA-11 PET scan

          -  Unable to tolerate PET scan (i.e. if the patient is claustrophobic or unable to lie
             still for 30-60 minutes)

          -  Subjects, who in the opinion of the investigator, may not be able to comply with the
             safety monitoring requirements of the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ammar Chaudhry</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ammar Chaudhry</last_name>
      <phone>626-218-6442</phone>
      <email>achaudhry@coh.org</email>
    </contact>
    <investigator>
      <last_name>Ammar Chaudhry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

